Myocardial viability assessed with fluorodeoxyglucose and pet in patients with q wave myocardial infarction receiving thrombolysis relationship to coronary anatomy and ventricular function

Nuclear Medicine Communications

Volumn 18, Issue 3, 1997, Pages 191-199

  Fragasso, Gabriele ^a   Chierchia, S L ^a   Rossetti, E ^a   Sciammarella, M G ^a   Conversano, A ^a   Lucignani, G ^a   Landoni, C ^a   Calori, G ^a   Margonato, A ^a   Fazio, F ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRINOLYTIC AGENT; FLUORODEOXYGLUCOSE F 18; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M;

ACUTE HEART INFARCTION; ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FIBRINOLYTIC THERAPY; HEART FUNCTION; HEART LEFT VENTRICLE FUNCTION; HEART VENTRICULOGRAPHY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; POSITRON EMISSION TOMOGRAPHY;

EID: 8244250123     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1080/00006231-199703000-00002     Document Type: Article

References (64)

1. The TIMI Study Group. Special report: The Thrombolysis in Myocardial Infarction (TIMI) Trial. N Eng J Med 1985; 312: 932-936.
2. Gruppo Italia per lo Studio della Streptochinasi nell'Infarto Miocardio. Long-term effects of intravenous thrombolysis in acute myocardial infarction: Final report of the GISSI Study. Lancet 1987; 2: 871-874.
3. ISIS 2 Collaborative Group. Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS 2. Lancet 1988; 2: 349-360.
4. Wilcox RG, Olsson CB, Skene AM et al. Trial of tissue plasminogen activator for mortality reduction in acute myocardial infarction: Anglo-Scandinavian Study of Early Thrombolysis (ASSET). Lancet 1988; 2: 525-530.
5. The AIMS Trial Study Group. Effect of intravenous APSAC on mortality after acute myocardial infarction: Preliminary report of a placebo-controlled clinical trial. Lancet 1988; 1: 545-549.
6. Reimer KA, Lowe JE, Rasmussen MM et al. The wavefront phenomenon of ischemic cell death, I. Myocardial infarct size vs duration of coronary occlusion in dogs. Circulation 1977; 56: 786-794.
7. Lavallee M, Cox D, Patrick TA et al. Salvage of myocardial function by coronary artery reperfusion 1, 2, and 3 hours after occlusion in conscious dogs. Circ Res 1983; 53: 235-247.
8. Bergmann SR, Lerch RA, Fox KAA et al. Temporal dependence of beneficial effects of coronary thrombolysis characterized by positron tomography. Am J Med 1982; 73: 573-581.
9. Schwartz F, Schuler G, Katus H et al. Intracoronary thrombolysis in acute myocardial infarction: Duration of ischemia as a major determinant of late results after recanalizaton. Am J Cardiol 1982; 50: 933-937.
10. Knabb RM, Bergmann SR, Fox KAA et al The temporal pattern of recovery of myocardial perfusion and metabolism delineated by positron emission topography after coronary thrombolysis. J Nucl Med 1987; 28: 1563-1570
11. Reimer KA, Jennings RB, Cobb FR et al. Animal models for protecting ischemic myocardium: Results of the NHLBI Cooperative Study. Comparison of unconscious and conscious dog models. Circ Res 1985; 56: 651-665.
12. White HD, Norris RM, Brown MA et al. Effect of intravenous streptokinase on left ventricular function and early survival after acute myocardial infarction. N Enç J Med 1987; 314: 850-855.
13. Bassand J-P, Faivre R, Becque O et al. Effects of early high-dose streptokinase on left ventricular function in acute myocardial infarction. Am J Cardiol 1987; 60: 435-439.
14. Kennedy JW, Martin CV, Davis KB et al. The Western Washington intravenous streptokinase in acute myocardial infarction randomized trial. Circulation 1988; 77: 345-352.
15. Meinertz T, Kasper W, Schumacher M et al. The German multicenter trial anisoylated plasminogen streptokinase activator complex versus heparin for acute myocardial infarction. Am J Cardiol 1988; 62: 347-351.
16. O’Rourke M, Baron D, Keogh A et al. Limitation of myocardial infarction by early infusion of recombinant tissue-type plasminogen activator. Circulation 1988; 77: 1311-1315.
17. National Heart Foundation of Australia Coronary Thrombolysis Group. Coronary thrombolysis and myocardial salvage by tissue plasminogen activator given up to 4 hours after onset of myocardial infarction. Lancet 1988; 1: 203-208.
18. Armstrong PW, Baigrie RS, Daly PA et al. Tissue plasminogen activator: Toronto (TPAT) placebo-controlled randomized trial in acute myocardial infarction. J Am Coll Cardiol 1989; 13: 1469-1476.
19. Van de Werf F, Arnold AER and the European Cooperative Study Group for Recombinant Tissue-Type Plasminogen Activator (rt-PA). Effect of intravenous tissue plasminogen activator on infarct size, left ventricular function and survival in patients with acute myocardial infarction. Br Med J 1988; 297: 1374-1379.
20. Van Lierde J, De Geest H, Verstraete M et al. Angiographic assessment of infarct-related residual coronary stenosis after spontaneous or therapeutic thrombolysis. J Am Coll Cardiol 1990; 16: 1545-1549.
21. Rentrop KP, Feit F, Blanke H et al. Serial angiographic assessment of coronary artery obstruction and collateral flow in acute myocardial infarction. Circulation 1989; 80: 1166-1175.
22. Ratib O, Phelps ME, Huang SC et al. Positron tomography with deoxyglucose for estimating local myocardial glucose metabolism. J Nucl Med 1982; 23: 577-586.
23. Brunken R, Tillish J, Schwaiger M et al. Regional perfusion, glucose metabolism and wall motion in patients with chronic electrocardiographic Q wave infarctions: Evidence for persistence of viable tissue in some infarct regions by positron emission tomography. Circulation 1986; 73: 951-963.
24. Tillish J, Brunken R, Marshall R et al. Reversibility of cardiac wall-motion abnormalities predicted by positron tomography. N Engl J Med 1986; 314: 884-888.
25. Tamaki N, Ohtani H, Yamashita K et al. Metabolic activity in the areas of new fill-in after thallium-201 reinjection: Comparison with positron emission tomography using fluorine-18-deoxyglucose. J Nucl Med 1991; 32: 673-678.
26. Lucignani G, Paolini G, Landoni C et al. Presurgical identification of hibernating myocardium by combined use of 99mTc MIBI/SPET and 18F-FDG/PET in patients with coronary artery disease. Eur J Nucl Med 1992; 19: 874-881.
27. Fudo T, Kambara H, Hashimoto T et al. F-18 deoxyglucose and stress N-13 ammonia positron emission tomography in anterior wall healed myocardial infarction. Am J Cardiol 1988; 61: 1191-1197.
28. Cohen M, Rentrop KP. Limitation of myocardial ischaemia by collateral circulation during sudden controlled coronary occlusion in human subjects: A prospective study. Circulation 1986; 74: 469-176.
29. Hamacher K, Coenen HH, Stocklin G. Efficient stereo-specific synthesis of no-carrier-added 2-18F-fluoro-2-deoxy-D-glucose using aminopolyether supported nucleo-philic substitution. J Nucl Med 1986; 27: 235-238.
30. Schwaiger M, Brunken RC, Krivokapich J et al. Beneficial effect of residual anterograde flow on tissue viability as assessed by positron emission tomography in patients with myocardial infarction. Eur Heart J 1987; 8: 981-988.
31. De Boer LWV, Ingwall JS, Kloner RA et al. Prolonged derangements of canine myocardial purine metabolism after a brief coronary artery occlusion not associated with anatomic evidence of necrosis. Proc Natl Acad Sci USA 1980; 77: 5471-5475.
32. Reimer KA, Hill ML, Jennings RB. Prolonged depletion of ATP and of the adenine nucleotide pool due to delayed resynthesis of adenine nucleotides following reversible myocardial ischemic injury in dogs. J Mol Cell Cardiol 1981; 13: 229-239.
33. Preuss KC, Gross GJ, Brooks H et al. Time course of recovery of 'stunned' myocardium following variable periods of ischaemia in conscious and anesthetized dogs. Am Heart J 1987; 114: 696-703.
34. Charlat ML, O'Neil PG, Hartley CJ et al. Prolonged abnormalities of left ventricular diastolic wall thinning in the 'stunned' myocardium in conscious dogs: Time course and relation to systolic function. J Am Coll Cardiol 1989; 13: 185-194.
35. Rentrop P, Blanke H, Karsh KR. Changes in left ventricular function after intracoronary streptokinase infusion in clinically evolving myocardial infarction. Am Heart J 1981; 102: 1188-1193.
36. Charuzi Y, Beeder C, Marshall LA et al. Improvement in regional and global left ventricular function after intracoronary thrombolysis: Assessment with two-dimensional echocardiography. Am J Cardiol 1984; 53: 662-665.
37. Reduto LA, Smalling RW, Freund GC et al. Intracoronary infusion of streptokinase in patients with acute myocardial infarction: Effects of reperfusion on left ventricular performance. Am J Cardiol 1981; 48: 403-409.
38. Braunwald E, Kloner RA. The stunned myocardium: Prolonged, postischemic ventricular dysfunction. Circulation 1982; 66: 1146-1149.
39. Camici P, Araujo LI, Spinks T et al. Increased uptake of 18F-fluorodeoxyglucose in postischemic myocardium of patients with exercise-induced angina. Circulation 1986; 74: 81-88.
40. Camici P, Kaski JC, Shea MJ et al. Selective increase of glucose utilization in the post-ischemic myocardium of patients with stable angina. In Maseri A, ed. Hammersmith Cardiology Workshop Series, Vol. 2. New York: Raven Press, 1985.
41. Sommers HM, Jennings RB. Experimental acute myocardial infarction: Histologic and histochemical studies of early myocardial infarcts induced by temporary or permanent occlusion of coronary artery. Lab Invest 1964; 13: 1491-1503.
42. Fantone JC, Ward PA. Role of oxygen-derived free radicals and metabolites in leukocyte-dependent inflammatory reaction. Am J Patlwl 1982; 107: 397-418.
43. Wijns W, Melin JA, Leners N et al. Accumulation of polymorphonuclear leukocytes in reperfused ischemic canine myocardium: Relation with tissue viability assessed by fluorine-18-2-deoxyglucose uptake. J Nucl Med 1986; 29: 1826-1832.
44. Kennedy JW, Ritchie JL, Davis KB et al. Western Washington randomized trial of intracoronary streptokinase in acute myocardial infarction. N Engl J Med 1983; 309: 1477-1482.
45. Ritchie JL, Davis KB, Williams DL et al. Global and regional left ventricular function and tomographic radionuclide perfusion: The Western Washington intracoronary streptokinase in acute myocardial infarction trial. Circulation 1984; 70: 867-875.
46. Kennedy JW, Ritchie JL, Davis KB et al. The Western Washington randomized trial of intracoronary streptokinase in acute myocardial infarction: A 12 month follow-up report. N Engl J Med 1985; 312: 1073-1078.
47. Stadius ML, Davis K, Maynard C et al. Risk stratification for 1 year survival based on characteristics identified in the early hours of acute myocardial infarction. Circulation 1989; 79: 441-144.
48. Braunwald E. Myocardial reperfusion, limitation on infarct size, reduction of left ventricular dysfunction and improved survival. Circulation 1989; 79: 441-44.
49. Rahimtoola SH. A perspective on the three large multicenter randomized clinical trials of coronary bypass surgery for chronic stable angina. Circulation 1985; 72: 123.
50. Bush LR, Buja LM, Samowitz W et al. Recovery of left ventricular segmental function after long-term reperfusion following temporary coronary occlusion in conscious dogs. Circ Res 1983; 53: 248-263.
51. Falsetti HL, Marcus ML, Kerber RE et al. Quantification of myocardial ischemia and infarction by left ventricular imaging. Circulation 1981; 63: 747-751.
52. Hammerman H, O'Boyle JE, Cohen C et al. Dissociation between two-dimensional echocardiographic left ventricular wall motion and myocardial salvage in early experimental acute myocardial infarction in dogs. Am j Cardiol 1984; 54: 875-879.
53. Hylton I, Miller MB, Almagor Y et al. Early intervention in acute myocardial infarction: Significance for myocardial salvage of immediate intravenous streptokinase therapy followed by coronary angioplasty. J Am Coll Cardiol 1987; 9: 608-614.
54. The TIMI Group. Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction: Results of the Thrombolysis in Myocardial Infarction (TIMI) phase II trial. N Engl J Med 1989; 320: 618-627.
55. Barbash GI. Randomized controlled trial of late in-hospital angiography and angioplasty vs conservative management after rt-PA treatment in acute myocardial infarction (abstract). J Am Coll Cardiol 1990; 15: 76A.
56. Baim DS, Braunwald E, Feit F et al. The Thrombolysis in Myocardial Infarction (TIMI) Trial phase II: Additional information and perspectives.J Am Coll Cardiol 1990; 15: 1188-1192.
57. Bianco JA, Sebree L, Subramanian R et al. C-14-deoxy-glucose accumulation in myocardial infarction (abstract). J Nucl Med 1990; 31: 835.
58. Gould KL, Haynie M, Hess MJ, Haynie M, Mullani N, Smalling RW. Myocardial metabolism of fluorodeoxy-glucose compared to cell membrane integrity for the potassium analogue Rb-82 for assessing infarct size in man by PET. J Nucl Med 1991; 32: 1-9.
59. Yaoita H, Juweid M, Wilkinson R et al. Detection of myocardial reperfusion injury with Tc-99m-glucarate (abstract). J Nucl Med 1990; 31: 795.
60. Fragasso G, Chierchia S, Lucignani G et al. Time dependence of residual tissue viability after myocardial infarction assessed by [IKF]fluorodeoxyglucose and positron emission tomography. Am J Cardiol 1993; 72: 131G-139G.
61. Marwick TH, MacIntyre WJ, Lafont A et al. Metabolic responses of hibernating and infarcted myocardium to revascularization: A follow-up study of regional perfusion, function and metabolism. Circulation 1992; 85: 1347-1353.
62. Pierard LA, De Landsheere CM, Berthe C et al. Identification of viable myocardium by echocardiography during dobutamine infusion in patients with myocardial infarction after thrombolytic therapy: Comparison with positron emission tomography. J Am Coll Cardiol 1990; 15: 1021-1031.
63. Bonow RO, Dilsizian V, Cuocolo A et al. Identification of viable myocardium in patients with chronic coronary artery disease and left ventricular dysfunction: Comparison of thallium scintigraphy with reinjection and PET imaging with F-18-fluorodeoxyglucose. Circulation 1991; 83: 26-37.
64. Margonato A, Chierchia SL, Xuereb RG et al. Specificity and sensitivity of exercise-induced ST segment elevation for detection of residual viability: Comparison with fluoro-deoxyglucose and positron emission tomography. J Am Coll Cardiol 1995; 25: 1032-1038.